Floatz logo

Axitinib

Neoadjuvant

ZHOU FANGJIANSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Neoadjuvant cohort.

Asset / SponsorPhaseRating
Toripalimab
ZHOU FANGJIAN
Phase 3B
Irinotecan
AbbVie
Phase 2CCC
Mirvetuximab Soravtansine
AbbVie
Phase 2CCC
TRASTUZUMAB
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2CCC
(+)-VINCRISTINE
AbbVie
Phase 2CCC

View all 11 →

Same molecule, other indications

Axitinib is also rated in:

kidney neoplasmDormant
BB
Indicative ·
69 / 100
View asset →
Kidney NeoplasmDormant
BB
Indicative ·
67 / 100
View asset →
renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →